TY  - JOUR
AU  - Ringborg, Ulrik
AU  - Berns, Anton
AU  - Celis, Julio E
AU  - Heitor, Manuel
AU  - Tabernero, Josep
AU  - Schüz, Joachim
AU  - Baumann, Michael
AU  - Henrique, Rui
AU  - Aapro, Matti
AU  - Basu, Partha
AU  - Beets-Tan, Regina
AU  - Besse, Benjamin
AU  - Cardoso, Fátima
AU  - Carneiro, Fátima
AU  - van den Eede, Guy
AU  - Eggermont, Alexander
AU  - Fröhling, Stefan
AU  - Galbraith, Susan
AU  - Garralda, Elena
AU  - Hanahan, Douglas
AU  - Hofmarcher, Thomas
AU  - Jönsson, Bengt
AU  - Kallioniemi, Olli
AU  - Kásler, Miklós
AU  - Kondorosi, Eva
AU  - Korbel, Jan
AU  - Lacombe, Denis
AU  - Carlos Machado, José
AU  - Martin-Moreno, José M
AU  - Meunier, Francoise
AU  - Nagy, Péter
AU  - Nuciforo, Paolo
AU  - Oberst, Simon
AU  - Oliveiera, Júlio
AU  - Papatriantafyllou, Maria
AU  - Ricciardi, Walter
AU  - Roediger, Alexander
AU  - Ryll, Bettina
AU  - Schilsky, Richard
AU  - Scocca, Grazia
AU  - Seruca, Raquel
AU  - Soares, Marta
AU  - Steindorf, Karen
AU  - Valentini, Vincenzo
AU  - Voest, Emile
AU  - Weiderpass, Elisabete
AU  - Wilking, Nils
AU  - Wren, Amanda
AU  - Zitvogel, Laurence
TI  - The Porto European Cancer Research Summit 2021.
JO  - Molecular oncology
VL  - 15
IS  - 10
SN  - 1878-0261
CY  - Hoboken, NJ
PB  - John Wiley & Sons, Inc.
M1  - DKFZ-2021-02043
SP  - 2507-2543
PY  - 2021
N1  - 2021 Oct;15(10):2507-2543
AB  - Key stakeholders from the cancer research continuum met in May 2021 at the European Cancer Research Summit in Porto to discuss priorities and specific action points required for the successful implementation of the European Cancer Mission and Europe's Beating Cancer Plan (EBCP). Speakers presented a unified view about the need to establish high-quality, networked infrastructures to decrease cancer incidence, increase the cure rate, improve patient's survival and quality of life, and deal with research and care inequalities across the European Union (EU). These infrastructures, featuring Comprehensive Cancer Centres (CCCs) as key components, will integrate care, prevention and research across the entire cancer continuum to support the development of personalized/precision cancer medicine in Europe. The three pillars of the recommended European infrastructures - namely translational research, clinical/prevention trials and outcomes research - were pondered at length. Speakers addressing the future needs of translational research focused on the prospects of multiomics assisted preclinical research, progress in Molecular and Digital Pathology, immunotherapy, liquid biopsy and science data. The clinical/prevention trial session presented the requirements for next-generation, multicentric trials entailing unified strategies for patient stratification, imaging, and biospecimen acquisition and storage. The third session highlighted the need for establishing outcomes research infrastructures to cover primary prevention, early detection, clinical effectiveness of innovations, health-related quality-of-life assessment, survivorship research and health economics. An important outcome of the Summit was the presentation of the Porto Declaration, which called for a collective and committed action throughout Europe to develop the cancer research infrastructures indispensable for fostering innovation and decreasing inequalities within and between member states. Moreover, the Summit guidelines will assist decision making in the context of a unique EU-wide cancer initiative that, if expertly implemented, will decrease the cancer death toll and improve the quality of life of those confronted with cancer, and this is carried out at an affordable cost.
KW  - Cancer Mission (Other)
KW  - cancer research/care/prevention continuum (Other)
KW  - clinical/prevention trials (Other)
KW  - comprehensive cancer centres (Other)
KW  - infrastructures for translational cancer research (Other)
KW  - outcomes research (Other)
KW  - science policy (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:34515408
DO  - DOI:10.1002/1878-0261.13078
UR  - https://inrepo02.dkfz.de/record/170609
ER  -